ROLE OF HELICOBACTER PYLORI ERADICATION USING CLARITHROMYCIN-BASED TRIPLE THERAPY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME
Ramadan, H., Ahmed, G., Hassan, W. (2022). ROLE OF HELICOBACTER PYLORI ERADICATION USING CLARITHROMYCIN-BASED TRIPLE THERAPY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME. EKB Journal Management System, 45(2), 859-868. doi: 10.21608/bfsa.2022.271687
Haidi Karam-Allah Ramadan; Gellan K. Ahmed; Waleed Attia Hassan. "ROLE OF HELICOBACTER PYLORI ERADICATION USING CLARITHROMYCIN-BASED TRIPLE THERAPY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME". EKB Journal Management System, 45, 2, 2022, 859-868. doi: 10.21608/bfsa.2022.271687
Ramadan, H., Ahmed, G., Hassan, W. (2022). 'ROLE OF HELICOBACTER PYLORI ERADICATION USING CLARITHROMYCIN-BASED TRIPLE THERAPY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME', EKB Journal Management System, 45(2), pp. 859-868. doi: 10.21608/bfsa.2022.271687
Ramadan, H., Ahmed, G., Hassan, W. ROLE OF HELICOBACTER PYLORI ERADICATION USING CLARITHROMYCIN-BASED TRIPLE THERAPY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME. EKB Journal Management System, 2022; 45(2): 859-868. doi: 10.21608/bfsa.2022.271687

ROLE OF HELICOBACTER PYLORI ERADICATION USING CLARITHROMYCIN-BASED TRIPLE THERAPY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME

Bulletin of Pharmaceutical Sciences Assiut University
Volume 45, Issue 2, December 2022, Page 859-868  XML PDF (907.78 K)
Document Type: Original Article
DOI: 10.21608/bfsa.2022.271687
View on SCiNiTO View on SCiNiTO
Authors
Haidi Karam-Allah Ramadan email 1; Gellan K. Ahmed* 2; Waleed Attia Hassan* 3
1Tropical Medicine and Gastroenterology, Faulty of Medicine, Assiut University.
2Department of Neurology and Psychiatry, Faculty of Medicine, Assiut University, Assiut, Egypt -Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK
3Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut, Egypt
Abstract
Background: Association between Helicobacter pylori (H. pylori) and irritable bowel syndrome (IBS) remains controversial. We evaluated the changes in symptoms and quality of life (QOL) in IBS patients following H. pylori eradication using clarithromycin-based triple therapy. Methods: Patients with moderate or severe IBS and positive H. pylori stool antigen were included and received clarithromycin-based triple therapy, followed by testing for H. pylori eradication after one month. IBS symptoms and IBS-QOL questionnaire were evaluated at the baseline and after H. pylori eradication. Results: 108 patients had H. pylori eradication. Following eradication, 66 patients reported IBS symptoms improvement, while 42 did not. The improved patients were significantly younger; mean age was 38.1 ± 11.7 (p= 0.03). IBS-C type predominated (42.4%) and postprandial fullness and early satiety as dyspeptic symptoms were higher in the improved group. The non-improved group showed a decrease in IBS-QOL subscales, significantly observed in dysphoria, interference with activity, health worry, and social reaction domains. The total IBS-QOL score was significantly higher in the improved versus the non-improved group (p= 0.000). Conclusion: H. pylori eradication did not improve IBS symptoms or QOL in all patients with IBS. QOL improved in young patients with dyspeptic symptoms and the IBS-C subtype.
Keywords
Eradication; Helicobacter pylori; irritable bowel syndrome; quality of life; triple therapy
Statistics
Article View: 244
PDF Download: 230